Clinical trials in Ranica – page 89

2 668 clinical trials in Ranica, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in ItalyStudi-Clinici.it

Ranica at a glance

2 668

clinical trials

Research sites1

Quick filters

2 668 trials in Ranica

Open in trial search

Oesophageal adenocarcinoma

Not yet recruiting

Phase II study of tislelizumab plus drug combination as intensified neoadjuvant and adjuvant therapy for resectable esophageal adenocarcinoma patients

Registered drugNo placebo

Phase II study of tislelizumab plus drug combination as intensified neoadjuvant and adjuvant therapy for resectable esophageal adenocarcinoma patients

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Centro Di Riferimento Oncologico Di Aviano

Contact Research Centre

Bronchiectasis

Not yet recruiting

Efficacy and safety of galvokimig in adults with non‑cystic fibrosis bronchiectasis: a randomized, double‑blind, placebo‑controlled phase 2 trial

Investigational

Efficacy and safety of galvokimig in adults with non‑cystic fibrosis bronchiectasis: a randomized, double‑blind, placebo‑controlled phase 2 trial

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Galvokimig
Sponsor:UCB Biopharma

Contact Research Centre

Hormone-refractory prostate cancer

Not yet recruiting

Randomized phase III study of AAA817 plus an androgen receptor pathway inhibitor in adult men with PSMA‑positive metastatic castration‑resistant prostate cancer

Registered drugNo placebo

Randomized phase III study of AAA817 plus an androgen receptor pathway inhibitor in adult men with PSMA‑positive metastatic castration‑resistant prostate cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Abiraterone
Sponsor:Novartis Pharma AG

Contact Research Centre

Familial hypertriglyceridaemia

Not yet recruiting

Open-Label Study of plozasiran in Adolescents Aged 12 to <18 Years with Familial Chylomicronemia Syndrome

Registered drugNo placebo

Open-Label Study of plozasiran in Adolescents Aged 12 to <18 Years with Familial Chylomicronemia Syndrome

Registered drugNo placebo

Italy

Participants:0–17 years
Sponsor:Arrowhead Pharmaceuticals Inc.

Contact Research Centre

Obesity+1

Not yet recruiting

A Phase III Study of Once‑Weekly Petrelintide to Evaluate Efficacy and Safety for Weight Loss in Adults with Overweight or Obesity

Investigational

A Phase III Study of Once‑Weekly Petrelintide to Evaluate Efficacy and Safety for Weight Loss in Adults with Overweight or Obesity

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Petrelintide
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Bronchitis+1

Not yet recruiting

Study of galvokimig versus placebo to assess safety and effectiveness in adults with moderate‑to‑severe chronic obstructive pulmonary disease with chronic bronchitis

Investigational

Study of galvokimig versus placebo to assess safety and effectiveness in adults with moderate‑to‑severe chronic obstructive pulmonary disease with chronic bronchitis

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Galvokimig
Sponsor:UCB Biopharma

Contact Research Centre

Idiopathic pulmonary fibrosis

Not yet recruiting

Phase 2 Study of Inhaled AGMB-447 and Salbutamol Sulfate in Adults with Idiopathic Pulmonary Fibrosis to Evaluate Lung Function, Safety and Tolerability

Registered drug

Phase 2 Study of Inhaled AGMB-447 and Salbutamol Sulfate in Adults with Idiopathic Pulmonary Fibrosis to Evaluate Lung Function, Safety and Tolerability

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Salbutamol Sulfate
Sponsor:Agomab Spain S.L.U.

Contact Research Centre

Primary biliary cholangitis

Not yet recruiting

Saroglitazar hemimagnesium normalizes alkaline phosphatase in primary biliary cholangitis patients with incomplete response or intolerance to ursodeoxycholic acid

Investigational

Saroglitazar hemimagnesium normalizes alkaline phosphatase in primary biliary cholangitis patients with incomplete response or intolerance to ursodeoxycholic acid

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Saroglitazar hemimagnesium
Sponsor:Zydus Therapeutics Inc.

Contact Research Centre

Non-small cell lung cancer

Not yet recruiting

Phase III Study of Izalontamab Brengitecan with Drug Combination versus Osimertinib Alone in First‑Line EGFR‑Mutated Advanced or Metastatic Non‑Small Cell Lung Cancer

Registered drugNo placebo

Phase III Study of Izalontamab Brengitecan with Drug Combination versus Osimertinib Alone in First‑Line EGFR‑Mutated Advanced or Metastatic Non‑Small Cell Lung Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Transitional cell carcinoma+1

Not yet recruiting

Phase 3 Study of trastuzumab brengitecan versus platinum‑based chemotherapy in adults with HER2‑positive metastatic urothelial cancer after anti‑PD‑(L)1 therapy

Registered drugNo placebo

Phase 3 Study of trastuzumab brengitecan versus platinum‑based chemotherapy in adults with HER2‑positive metastatic urothelial cancer after anti‑PD‑(L)1 therapy

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Systimmune Inc.

Contact Research Centre

Facioscapulohumeral muscular dystrophy

Not yet recruiting

Phase 2 Study of Apitegromab in Patients with Facioscapulohumeral Muscular Dystrophy

Registered drug

Phase 2 Study of Apitegromab in Patients with Facioscapulohumeral Muscular Dystrophy

Registered drug

Italy

Participants:18–64 years
Substances:Apitegromab
Sponsor:Scholar Rock Inc.

Contact Research Centre

Chronic coronary syndrome

Not yet recruiting

Effect of Inclisiran, Ezetimibe and Statin Therapy on LDL‑C Levels in Patients with Chronic Coronary Syndrome or Prior Myocardial Infarction

Registered drugNo placebo

Effect of Inclisiran, Ezetimibe and Statin Therapy on LDL‑C Levels in Patients with Chronic Coronary Syndrome or Prior Myocardial Infarction

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Inclisiran
Sponsor:Policlinico San Donato S.p.A.

Contact Research Centre

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Ranica

What the registry says about research in the country

01 Glomerulonephritis Studies

Innovative research focusing on membranoproliferative glomerulonephritis and related conditions, evaluating novel therapeutic approaches including iptacopan and pegcetacoplan for treating various forms of kidney inflammation.

IC-MPGN Treatment Evaluation
C3 Glomerulopathy Research
Post-Transplant Recurrence Studies

Multiple trials aim to reduce proteinuria and improve long-term kidney function outcomes.

02 Nephropathy Research

Comprehensive studies examining treatments for IgA Nephropathy and membranous nephropathy, including investigations of sparsentan and specialized antibody therapies for patients resistant to conventional treatments.

Primary Membranous Nephropathy
IgA Nephropathy Interventions
Antibody-Based Treatments

Focus on proteinuria reduction and preservation of renal function in various nephropathy types.

03 Chronic Kidney Disease

Advanced research into non-diabetic chronic kidney disease, exploring new therapeutic options including finerenone and investigating treatments for complications like hyperkalemia.

Disease Progression Prevention
Hyperkalemia Management
Long-term Kidney Function

Studies aim to delay disease progression and improve standard of care outcomes.

Back to Italy All countries